INTERIM REPORT JANUARY-JUNE 2023
2023-08-29 05:52
SECOND QUARTER, APRIL-JUNE 2023
- Net sales amounted to MSEK 0.0 (0.0)
- Operating loss (EBIT) amounted to MSEK -5.9 (-8.7)
- Net loss amounted to MSEK -5.9 (-8.7)
- Net cash flow amounted to MSEK 18.3 (3.8)
- EPS before and after dilution amounted to SEK -0.12 (-0.37)
JANUARY-JUNE 2023
- Net sales amounted to MSEK 0.0 (0.0)
- Operating loss (EBIT) amounted to MSEK -12.2 (-16.0)
- Net loss amounted to MSEK -12.8 (-16.0)
- Net cash flow amounted to MSEK 12.3 (-1.7)
- EPS before and after dilution amounted to SEK -0.34 (-0.73)
SIGNIFICANT EVENTS
- In April, the subsidiary Amplicon launched its first product, småå®, the new concept within white, dry, tobacco free, nicotine pouches.
- In May, the EGM resolved to adopt new articles of association in accordance with the board of directors' proposal, entailing amendments of the limits of the share capital and the number of shares.
- In May, the company carried out a directed issue of new shares of MSEK 25.0 to TomEQT Private AB.
- Also in May, TomEQT Private AB announced a mandatory takeover offer in cash for the shares in Emplicure AB (publ) at a price of SEK 0.50 per share.
- At the AGM In June, Jonas Ekblom and Anders Peteri were elected ordinary board members.
- In June, the board of directors of Emplicure AB recommended the shareholders of Emplicure not to accept the mandatory takeover offer of SEK 0.50 per share made by TomEQT Private AB.
This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on August 29, 2023 at 07.52 CET
För mer information, vänligen kontakta:
Håkan Engqvist
VD
Tel: +46 702 569 500
Email: hakan.engqvist@emplicure.com
Erik Magnusson
CFO
Tel: +46 708 565 245
Email: erik.magnusson@emplicure.com
Certified Adviser
Emplicure AB (publ) är noterat på Nasdaq First North Growth Market. Certified Adviser är Erik Penser Bank.
Följande dokument kan hämtas från beQuoted
Emplicure-Q223 ENG FINAL.pdf
Emplicure utvecklar nya innovativa produkter baserat på kombinationen av redan godkända aktiva substanser och avancerad materialvetenskap inom biokeramer. Produktportföljen fokuserar på läkemedel mot kronisk smärta och med egenskaper som motverkar att de kan missbrukas. Dotterbolaget Amplicon AB utvecklar konsumentprodukter med oralt nikotin som första produkt. Aktien är listad på Nasdaq First North Growth Market (EMPLI). Läs mer på www.emplicure.com